GlassScriptPhysician profile
Peter Wawrzusin
NPI 1235660051
$4,188.36
in general payments reported to CMS, 2019-2025
20 companies · $793 in 2025
The $793 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $152 · 2022: $281 · 2023: $539 · 2024: $2,423 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,353 · Travel and Lodging: $1,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,352.63 |
| Travel and Lodging | $1,402.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,927.86 | 2022-2024 | Lensx, Clareon, Rocklatan |
| Mallinckrodt Hospital Products INC. | $410.16 | 2021-2025 | Acthar |
| Bausch & Lomb Americas INC. | $320.01 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Biotissue Holdings INC. | $298.31 | 2023-2025 | |
| Tarsus Pharmaceuticals, INC. | $223.68 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $201.59 | 2024-2025 | Photrexa Viscous and Photrexa, Ce-Marked Kxla System |
| Oyster Point Pharma, INC. | $189.60 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Amgen INC. | $166.56 | 2024 | Tepezza |
| Dompe US, INC. | $142.07 | 2023-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $61.24 | 2023-2025 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $49.55 | 2022-2023 | Tecnis Iol |
| Eyevance Pharmaceuticals LLC | $44.04 | 2022 | |
| Rayner Intraocular Lenses Limited | $27.42 | 2025 | Omidria |
| Genentech USA, INC. | $24.88 | 2024 | Vabysmo |
| Rxsight INC | $22.81 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Injector Handpiece |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $18.89 | 2024 | Vevye |
| Horizon Therapeutics Plc | $17.28 | 2023 | Tepezza |
| Abbvie INC. | $15.24 | 2023 | Durysta |
| Johnson & Johnson Vision Care, INC. | $14.39 | 2023 | Acuvue |
| Novartis Pharmaceuticals Corporation | $12.78 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Wawrzusin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.